Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in CRSP.
← Back to Free Index

CRSP

Analysis as of: 2026-04-28
CRISPR Therapeutics AG
CRISPR Therapeutics develops gene-edited medicines across hemoglobinopathies, cardiometabolic disease, autoimmune disease, oncology, and regenerative medicine.
ai biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Approved Proof, Owned-Proof Still Pending
The five-year opportunity comes from turning landmark modality proof into a repeatable, internally controlled business. The balance sheet buys time, but the rerating still depends on one owned program crossing from promise to proof.

Analysis

Thesis
The five-year upside is not from CASGEVY alone; it is from turning first-in-class modality proof into a second, internally controlled franchise while using cash, IP, manufacturing know-how, and platform reuse to compound across in vivo editing and cell therapy.
Last Economy Alignment
AI should make target selection and design faster, but value capture still sits in patents, regulated evidence, manufacturing, and treatment trust. This is a real tailwind, not a pure software winner.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
3.1x (from 5 most recent analyses)
Reasoning
The upside case does not require three blockbusters. It requires CASGEVY to become a credible economics stream, one wholly owned asset to cross from promising biology into commercial reality, and the platform to show reuse across at least one more franchise. That would move the stock from cash-backed optionality to a multi-asset growth biotech, but the absence of broad late-stage proof keeps the outcome in the solid-upside range rather than true hypergrowth.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is proof conversion, not survival. CRISPR Therapeutics now has enough capital to wait for data, but the stock still needs one wholly owned program to move from encouraging science into durable efficacy, manageable safety, and scalable commercial fit. If CASGEVY remains partner-throttled and the owned pipeline stays early, the company can keep strategic relevance without earning a platform rerating.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.39
They own gene-editing know-how, patents, and manufacturing steps that are hard to copy, so AI can help them design better medicines faster without making the business easy to replace. The catch is that regulators, treatment centers, and a partner-led launch still control how quickly scientific wins turn into shareholder value.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$83.74
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case